CIK 0001875558
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Nuvectis Pharma, Inc.
Sign in to watch- Ticker
- NVCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 862405608
- Phone
- +1 360-837-7232
- Business address
- 1 BRIDGE PLAZA, SUITE 275, FORT LEE, NJ, 07024
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-13 | BENTSUR RON Chairman & CEO | Purchase | +700 | $18.10 | $13K | 2,958,404 |
| 2022-05-12 | Hoberman Kenneth Director | Purchase | +6,000 | $17.40 | $104K | 55,140 |
| 2022-05-12 | Kaplan Matthew L. Director | Purchase | +1,177 | $15.96 | $19K | 33,937 |
| 2022-05-12 | Kaplan Matthew L. Director | Purchase | +1,823 | $17.47 | $32K | 35,760 |
| 2022-05-12 | Poradosu Enrique Chief Science & Business Off | Purchase | +370 | $14.76 | $5K | 1,258,019 |
| 2022-05-12 | Poradosu Enrique Chief Science & Business Off | Purchase | +300 | $16.04 | $5K | 1,258,319 |
| 2022-05-12 | Shemesh Shay Chief Dev. & Ops. Officer | Purchase | +36 | $14.58 | $525 | 1,239,651 |
| 2022-05-12 | Shemesh Shay Chief Dev. & Ops. Officer | Purchase | +1,184 | $15.85 | $19K | 1,240,835 |
| 2022-05-12 | Shemesh Shay Chief Dev. & Ops. Officer | Purchase | +58 | $16.61 | $963 | 1,240,893 |
| 2022-05-12 | BENTSUR RON Chairman & CEO | Purchase | +1,100 | $14.88 | $16K | 2,946,559 |
| 2022-05-12 | BENTSUR RON Chairman & CEO | Purchase | +600 | $16.12 | $10K | 2,947,159 |
| 2022-05-12 | BENTSUR RON Chairman & CEO | Purchase | +10,545 | $17.26 | $182K | 2,957,704 |
| 2022-04-01 | Kaplan Matthew L. Director | Grant or award · Stock Options (right to buy) | +15,000 | 15,000 | ||
| 2022-04-01 | Hoberman Kenneth Director | Grant or award · Stock Options (right to buy) | +15,000 | 15,000 | ||
| 2022-04-01 | Oliviero James F III Director | Grant or award · Stock Options (right to buy) | +15,000 | 15,000 | ||
| 2022-04-01 | Poradosu Enrique Chief Science & Business Off | Grant or award | +60,000 | 1,257,649 | ||
| 2022-04-01 | Shemesh Shay Chief Dev. & Ops. Officer | Grant or award | +60,000 | 1,239,615 | ||
| 2022-04-01 | BENTSUR RON Chairman & CEO | Grant or award | +120,000 | 2,945,459 | ||
| 2022-03-28 | BENTSUR RON Chairman & CEO | Purchase | +4,000 | $7.05 | $28K | 2,825,459 |
| 2022-03-17 | BENTSUR RON Chairman & CEO | Purchase | +7,000 | $7.63 | $53K | 2,821,459 |
Page 9 of 10 · 190 trades